Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous

Blood Purification Clinical Trial

Official title:

Preliminary Study on the Effect of Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05510713
• Other study ID #: jv-fv-RRT
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 1, 2022
• Est. completion date: October 1, 2024

Study information

• Verified date: August 2022
• Source: Shanghai Zhongshan Hospital
• Contact: Zhunyong Gu
• Phone: 8613918677995
• Email: gu.zhunyong[@]zs-hospital.sh.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acute kidney failure (AKI) is one of the most important causes of morbidity and mortality for critical ill patients. The use of blood purification treatment such as renal replacement therapy (CRRT) and plasma exchange has gradually developed into an effective treatment. However, the efficiency of blood purification may be affected by the recirculation of dual-lumen venous catheter for some special patients including patients with vena cava reflux disorder from massive occupations or ascites. For extreme cases like patients with vena cava disconnection or severe obstruction, the traditional blood purification treatment cannot work effectively. Thus, we used the dual-cannula in jugular-femoral venous blood purification therapy in the following two patients and found that it can improve the perfusion of systemic circulation and the prognosis of patients

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: October 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 1. patients requiring haemodilution therapy for various reasons (acute renal failure, acute liver failure, etc.)

• 2. presence of superior vena cava and/or inferior vena cava reflux disorders

• 3. age greater than 18 years

Exclusion Criteria:

• 1. Inability to establish suitable vascular access

• 2. Pregnant women

• 3. Not agreeing to active life support treatment

• 4. Severe active bleeding

Related Conditions & MeSH terms

• Blood Purification

Intervention

Device:
• Hemodialysis Catheter
We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	vasoactive drugs	doses of vasoactive drugs	144 hours after dual-cannula in jugular-femoral venous
Primary	ICU mortality	Measurement of ICU mortality	28-day ICU mortality
Secondary	Cytokine	Checking cytokine levels by laboratory	24hous after dual-cannula in jugular-femoral venous